ReviewOrphanet journal of rare diseases2026
Genetic and non-genetic factors influencing phenotypic variability in neurofibromatosis type 1.
Review in Orphanet journal of rare diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neurofibromatosis Type 1 (NF1), an autosomal dominant genetic disorder, is characterized by extensive clinical variability, posing significant challenges for prognosis and patient management. Despite being caused by mutations in a single gene, NF1, the expressivity of the disease ranges from mild cutaneous manifestations to severe, life-threatening complications, including malignant tumors, skeletal deformities, and cognitive impairments. This paper provides a comprehensive review of the genetic determinants underlying this phenotypic heterogeneity. We begin by elucidating the molecular genetics of NF1, detailing the structure and function of the NF1 gene and its protein product, neurofibromin, and the diverse spectrum of mutations that cause the disorder. Neurofibromin's critical role as a negative regulator of the Ras signaling pathway is central to understanding the pathophysiology of NF1. Subsequently, the paper explores the primary mechanisms driving phenotypic variation, including established genotype-phenotype correlations, the influence of genetic modifiers, the impact of somatic mosaicism and second-hit mutations, and the emerging role of epigenetic and environmental factors. By synthesizing current knowledge, this review aims to construct a holistic view of the complex interplay between the primary NF1 mutation and the broader genetic landscape that ultimately shapes the clinical presentation of NF1. Understanding these determinants is crucial for advancing diagnostic capabilities, developing personalized therapeutic strategies, and improving clinical outcomes for individuals affected by this complex disorder.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.